The Small Molecule GMX1778 Is a Potent Inhibitor of NAD + Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors

Poly(ADP-ribose): novel functions for an old molecule

Schreiber, V., Dantzer, F., Amé, J., & de MURCIA, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,975

Requirement of NAD and SIR2 for Life-Span Extension by Calorie Restriction in Saccharomyces cerevisiae

Lin, S.-J., Defossez, P.-A., & Guarente, L. (2000) · Science · doi:10.1126/science.289.5487.2126 · Cited by 1,775

The Sir2 Family of Protein Deacetylases

Blander, G., & Guarente, L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073651 · Cited by 1,497

A gene expression database for the molecular pharmacology of cancer

Scherf, U., Ross, D. T., Waltham, M. C., Smith, L. H., Lee, J. K., Tanabe, L. K., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450

Cloning and Characterization of the cDNA Encoding a Novel Human pre-B-Cell Colony-enhancing Factor

Samal, B. B., Sun, Y., Stearns, G., Xie, C., Suggs, S. V., & McNiece, I. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.2.1431 · Cited by 1,025

The NAD Biosynthesis Pathway Mediated by Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells

Revollo, J. R., Grimm, A. A., & Imai, S.-I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408388200 · Cited by 1,010

Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme

Revollo, J. R., Körner, A., Mills, K. F., Satoh, A., Wang, T., Garten, A., Dasgupta, B., Sasaki, Y., Wolberger, C., Townsend, R. R., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.003 · Cited by 911

The power to reduce: pyridine nucleotides—small molecules with a multitude of functions

Pollak, N., Dölle, C., & Ziegler, M. (2007) · Biochemical Journal · doi:10.1042/bj20061638 · Cited by 730

Nuclear ADP-Ribosylation Reactions in Mammalian Cells: Where Are We Today and Where Are We Going?

Hassa, P. O., Haenni, S. S., Elser, M., & Hottiger, M. O. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00040-05 · Cited by 719

NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177 Lu-DOTATATE Treatment of Neuroendocrine Tumors

Elf, A., Bernhardt, P., Hofving, T., Arvidsson, Y., Forssell-Aronsson, E. B., Wängberg, B., Nilsson, O., & Johanson, V. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.177584 · Cited by 42

Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours

Adant, S., Shah, G. M., & Beauregard, J. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04499-x · Cited by 41

APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells

Cagnetta, A., Caffa, I., Acharya, C., Soncini, D., Acharya, P. C., Adamia, S., Pierri, I., Bergamaschi, M., Garuti, A., Orcioni, G. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3023 · Cited by 40

Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors

Wang, W., Elkins, K., Oh, A., Ho, Y., Wu, J., Li, H., Xiao, Y., Kwong, M., Coons, M. M., Brillantes, B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109366 · Cited by 38

Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors

Wilsbacher, J. L., Cheng, M., Cheng, D., Trammell, S. A. J., Shi, Y., Guo, J. Q., Koeniger, S. L., Kovar, P. J., He, Y., Selvaraju, S., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0819 · Cited by 38

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation

Guo, J. Q., Lam, L. T., Longenecker, K. L., Bui, M. H., Idler, K. B., Glaser, K. B., Wilsbacher, J. L., Tse, C., Pappano, W. N., & Huang, T.-H. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.143 · Cited by 38

Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer

Bi, K., Cheng, J., He, S., Fang, Y., Huang, M., Sheng, C., & Dong, G. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01990 · Cited by 38

Efficacy of Combining GMX1777 with Radiation Therapy for Human Head and Neck Carcinoma

Kato, H., Ito, E., Shi, W., Alajez, N. M., Yue, S., Lee, C., Chan, N. H. L., Bhogal, N., Coackley, C. L., Vines, D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1945 · Cited by 37

Targeting NAD+ metabolism: dual roles in cancer treatment

Yong, J., Cai, S., & Zeng, Z.-L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269896 · Cited by 37

Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

Dragovich, P. S., Bair, K. W., Baumeister, T., Ho, Y., Liederer, B. M., Liu, X., Liu, Y., O’Brien, T., Oeh, J., Sampath, D., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.06.090 · Cited by 36

The efficacy of cholesterol-lowering action and side effects of garlic enteric coated tablets in man.

Tanamai, J., Veeramanomai, S., & Indrakosas, N. (2004) · PubMed · Cited by 35

Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin

Biedermann, J., Preussler, M., Conde, M., Peitzsch, M., Richter, S., Wiedemuth, R., Abou‐El‐Ardat, K., Krüger, A., Meinhardt, M., Schackert, G., et al. (2019) · Cancers · doi:10.3390/cancers11122028 · Cited by 36

Screening in serum-derived medium reveals differential response to compounds targeting metabolism

Abbott, K. L., Ali, A., Casalena, D. E., Do, B. T., Ferreira, R., Cheah, J. H., Soule, C. K., Deik, A., Kunchok, T., Schmidt, D. R., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.08.007 · Cited by 35

A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT

Barraud, M., Garnier, J., Loncle, C., Gayet, O., Lequeue, C., Vasseur, S., Bian, B., Duconseil, P., Gilabert, M., Bigonnet, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10776 · Cited by 33

Metabolomic signatures in lipid‐loaded HepaRGs reveal pathways involved in steatotic progression

Brown, M. V., Compton, S. A., Milburn, M. V., Lawton, K. A., & Cheatham, B. (2013) · Obesity · doi:10.1002/oby.20440 · Cited by 34

Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia

Somers, K., Evans, K., Cheung, L., Karsa, M., Pritchard, T., Kosciolek, A., Bongers, A., El‐Ayoubi, A., Forgham, H., Middlemiss, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0683-6 · Cited by 32

Radionuclide Therapy via SSTR: Future Aspects from Experimental Animal Studies

Forssell-Aronsson, E. B., Spetz, J. K. E., & Ahlman, H. (2012) · Neuroendocrinology · doi:10.1159/000336086 · Cited by 30

NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets

Indini, A., Fiorilla, I., Ponzone, L., Calautti, E., & Audrito, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179985 · Cited by 31

PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma

Gelmi, M. C., Gezgin, G., van der Velden, P. A., Luyten, G. P. M., Luk, S. J., Heemskerk, M. H. M., & Jager, M. J. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.15.36 · Cited by 30

Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines

Misner, D., Kauss, M. A., Singh, J., Uppal, H., Bruening‐Wright, A., Liederer, B. M., Lin, T., McCray, B., La, N., Nguyen, T. V., et al. (2016) · Cardiovascular Toxicology · doi:10.1007/s12012-016-9387-6 · Cited by 29

Inhibitors of NAD+ Production in Cancer Treatment: State of the Art and Perspectives

Ghanem, M. S., Caffa, I., Monacelli, F., & Nencioni, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042092 · Cited by 28

PARP and other prospective targets for poisoning cancer cell metabolism

Michels, J., Obrist, F., Castedo, M., Vitale, I., & Kroemer, G. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.08.026 · Cited by 28

Categorizing Ion –Features in Liquid Chromatography/Mass Spectrometry Metobolomics Data

Evans, A. M. (2012) · Journal of Postgenomics Drug & Biomarker Development · doi:10.4172/2153-0769.1000110 · Cited by 28

Drug discovery targeting nicotinamide phosphoribosyltransferase (NAMPT): Updated progress and perspectives

Wen, F., Gui, G., Wang, X., Li, Y., Qin, A., Zhou, C., & Zha, X. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117595 · Cited by 28

NAMPT and NAPRT1: novel polymorphisms and distribution of variants between normal tissues and tumor samples

Duarte-Pereira, S., Silva, S. S., Azevedo, L., Castro, L., Amorim, A., & Silva, R. M. (2014) · Scientific Reports · doi:10.1038/srep06311 · Cited by 29

Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death

Reddy, V. G., Krider, I. S., Alves, E. T. M., Courey, J. M., Laham, M. S., & Thatcher, G. R. J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02112 · Cited by 27

Attenuated SIRT1 Activity Leads to PER2 Cytoplasmic Localization and Dampens the Amplitude of Bmal1 Promoter-Driven Circadian Oscillation

Ashimori, A., Nakahata, Y., Sato, T., Fukamizu, Y., Matsui, T., Yoshitane, H., Fukada, Y., Shinohara, K., & Bessho, Y. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.647589 · Cited by 26

Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

Dragovich, P. S., Zhao, G., Baumeister, T., Bravo, B. J., Giannetti, A. M., Ho, Y., Hua, R., Li, G., Liang, X., Ma, X., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.062 · Cited by 26

Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy

Singh, N., Pay, S. L., Bhandare, S. B., Arimpur, U., & Motea, E. A. (2020) · Cancers · doi:10.3390/cancers12040972 · Cited by 24

The potential of metabolomic approaches for investigating mode(s) of action of xenobiotics: Case study with carbon tetrachloride

Vulimiri, S. V., Berger, A., & Sonawane, B. R. (2010) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2010.02.013 · Cited by 24

SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT)

Curtin, M. L., Heyman, H. R., Clark, R. F., Sorensen, B. K., Doherty, G. A., Hansen, T. M., Frey, R. R., Sarris, K., Aguirre, A. L., Shrestha, A., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.06.018 · Cited by 24

Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent

Cloux, A.-J., Aubry, D., Heulot, M., Widmann, C., ElMokh, O., Piacente, F., Cea, M., Nencioni, A., Bellotti, A., Bouzourène, K., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27336 · Cited by 23

The “Superoncogene” Myc at the Crossroad between Metabolism and Gene Expression in Glioblastoma Multiforme

Cencioni, C., Scagnoli, F., Spallotta, F., Nasi, S., & Illi, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044217 · Cited by 28

Complex role of nicotinamide adenine dinucleotide in the regulation of programmed cell death pathways

Preyat, N., & Léo, O. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.110 · Cited by 23

Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment

Ogino, Y., Sato, A., Uchiumi, F., & Tanuma, S.-I. (2018) · Oncotarget · doi:10.18632/oncotarget.24731 · Cited by 23

MicroRNA-494 induces breast cancer cell apoptosis and reduces cell viability by inhibition of nicotinamide phosphoribosyltransferase expression and activity

Ghorbanhosseini, S. S., Nourbakhsh, M., Zangooei, M., Abdolvahabi, Z., Bolandghamtpour, Z., Hesari, Z., Yousefi, Z., Panahi, G., & Meshkani, R. (2018) · EXCLI journal · doi:10.17179/excli2018-1748 · Cited by 22

Enzymatic and Chemical Syntheses of Vacor Analogs of Nicotinamide Riboside, NMN and NAD

Sverkeli, L. J., Hayat, F., Migaud, M. E., & Ziegler, M. (2021) · Biomolecules · doi:10.3390/biom11071044 · Cited by 22

Targeting DNA Polymerase ß for Therapeutic Intervention

Goellner, E. M., Svilar, D., Almeida, K. H., & Sobol, R. W. (2011) · Current Molecular Pharmacology · doi:10.2174/1874-470211205010068 · Cited by 31

Optimization of a urea-containing series of nicotinamide phosphoribosyltransferase (NAMPT) activators

Pinkerton, A. B., Sessions, E. H., Hershberger, P., Maloney, P., Peddibhotla, S., Hopf, M. E., Sergienko, E. A., Ma, C.-T., Smith, L. H., Jackson, M. R., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128007 · Cited by 22

Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery

Ghanem, M. S., Caffa, I., Río, A. D., Franco, J., Parenti, M. D., Monacelli, F., Cea, M., Khalifa, A., Nahimana, A., Duchosal, M. A., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15070848 · Cited by 23

A holistic approach for process intensification of nicotinamide mononucleotide production via high cell density cultivation under exponential feeding strategy

Kafle, S. R., Kushwaha, A., Goswami, L., Maharjan, A., & Kim, B. S. (2023) · Bioresource Technology · doi:10.1016/j.biortech.2023.129911 · Cited by 21

Crystal structure-based comparison of two NAMPT inhibitors

Zhang, S.-L., Xu, T., Yang, Z., Han, S., Zhao, Q., & Miao, C. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.80 · Cited by 21

Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase

Chen, W., Dong, G., He, S., Xu, T., Wang, X., Liu, N., Zhang, W., Miao, C., & Sheng, C. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.12.101 · Cited by 21

From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases

Zhu, Y., Xu, P., Huang, X., Wen, S., Liu, L., Zhang, S., Zhao, R., Hu, X., & Wang, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.920113 · Cited by 21

Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy

Kim, M., Kim, H., Kang, B.-G., Lee, J., Kim, T., Lee, H., Jung, J., Oh, M. J., Seo, S., Ryu, M., et al. (2023) · Theranostics · doi:10.7150/thno.85356 · Cited by 21

Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors

Zheng, X., Baumeister, T., Buckmelter, A. J., Caligiuri, M., Clodfelter, K. H., Han, B., Ho, Y., Kley, N., Lin, J., Reynolds, D. J., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.006 · Cited by 20

PBEF/NAMPT/Visfatin: A Promising Drug Target For Treating Rheumatoid Arthritis?

Nowell, M. A., Evans, L., & Williams, A. S. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.34 · Cited by 19

Clinical metabolomics for inborn errors of metabolism

Ford, L. A., Mitchell, M. W., Wulff, J. E., Evans, A. M., Kennedy, A. D., Elsea, S. H., Wittmann, B. M., & Toal, D. R. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2021.09.001 · Cited by 18

Secretion of One Adipokine Nampt/Visfatin Suppresses the Inflammatory Stress‐Induced NF‐κB Activity and Affects Nampt‐Dependent Cell Viability in Huh‐7 Cells

Lin, Y.-C., Wu, H.-C., Liao, C.-C., Chou, Y.-C., Pan, S.-F., & Chiu, C.-M. (2015) · Mediators of Inflammation · doi:10.1155/2015/392471 · Cited by 18

Metabolic Response to NAD Depletion across Cell Lines Is Highly Variable

Xiao, Y., Kwong, M., Daemen, A., Belvin, M. P., Liang, X., Hatzivassiliou, G., & O’Brien, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164166 · Cited by 18

Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy

Cole, J., Guiot, M., Gravel, M., Bernier, C., Shore, G. C., & Roulston, A. (2017) · Oncotarget · doi:10.18632/oncotarget.20840 · Cited by 17

Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells

Ogino, Y., Sato, A., Uchiumi, F., & Tanuma, S.-I. (2018) · Genomics · doi:10.1016/j.ygeno.2018.12.012 · Cited by 17

Serum Metabolomic Profiling Reveals the Amelioration Effect of Methotrexate on Imiquimod-Induced Psoriasis in Mouse

Zong, J., Cheng, J., Fu, Y., Song, J., Weisong, P., Yang, L., Zhang, T., & Zhou, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.558629 · Cited by 17

Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer

Kudo, K., Nomura, M., Sakamoto, Y., Ito, S., Morita, M., Kawai, M., Yamashita, Y., Ito, K., Yamada, H., Shima, H., et al. (2020) · FEBS Letters · doi:10.1002/1873-3468.13736 · Cited by 16

Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia

ElMokh, O., Matsumoto, S., Biniecka, P., Bellotti, A., Schaeuble, K., Piacente, F., Gallart‐Ayala, H., Ivanišević, J., Stamenkovic, I., Nencioni, A., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04763-3 · Cited by 16

How Does Fusarium oxysporum Sense and Respond to Nicotinaldehyde, an Inhibitor of the NAD+ Salvage Biosynthesis Pathway?

Anand, G., Waiger, D., Vital, N. Y., Maman, J., Ma, L., & Covo, S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00329 · Cited by 16

Measuring the Metabolic Evolution of Glioblastoma throughout Tumor Development, Regression, and Recurrence with Hyperpolarized Magnetic Resonance

Salzillo, T. C., Mawoneke, V., Weygand, J., Shetty, A., Gumin, J., Zacharias, N. M., Gammon, S. T., Piwnica-Worms, D. R., Fuller, G. N., Logothetis, C. J., et al. (2021) · Cells · doi:10.3390/cells10102621 · Cited by 15

Visfatin and Rheumatoid Arthritis: Pathogenetic Implications and Clinical Utility

Polyakova, Y. V., Zavodovsky, B. V., Sivordova, L. E., Akhverdyan, Y., & Zborovskaya, I. A. (2019) · Current Rheumatology Reviews · doi:10.2174/1573397115666190409112621 · Cited by 15

Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors

Tanuma, S.-I., Katsuragi, K., Oyama, T., Yoshimori, A., Shibasaki, Y., Asawa, Y., Yamazaki, H., Makino, K., Okazawa, M., Ogino, Y., et al. (2020) · Molecules · doi:10.3390/molecules25163633 · Cited by 15

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency

Bajrami, I., Walker, C., Krastev, D. B., Weekes, D. B., Song, F., Wicks, A. J., Alexander, J. J., Haider, S. A., Brough, R., Pettitt, S. J., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02770-2 · Cited by 16

Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia

Eldfors, S., Saad, J. J., Ikonen, N., Malani, D., Vähä-Koskela, M. J. V., Gjertsen, B. T., Kontro, M., Porkka, K., & Heckman, C. A. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010435 · Cited by 14

Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression

Franceschini, N., Oosting, J., Tamsma, M., Niessen, B., Bruijn, I. H. B., van den Akker, B., Kruisselbrink, A. B., Palubeckaitė, I., Bovée, J. V. M. G., & Cleton-Jansen, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126273 · Cited by 14

NAPRT Expression Regulation Mechanisms: Novel Functions Predicted by a Bioinformatics Approach

Duarte-Pereira, S., Fajarda, O., Matos, S., Oliveira, J. L., & Silva, R. M. (2021) · Genes · doi:10.3390/genes12122022 · Cited by 14

Fluorescent and theranostic probes for imaging nicotinamide phosphoribosyl transferase (NAMPT)

Sun, D., Dong, G., Wu, Y., Dong, G., Du, L., Li, M., & Sheng, C. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115080 · Cited by 13

Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models

McKay-Corkum, G. B., Collins, V. J., Yeung, C. L., Ito, T., Issaq, S. H., Holland, D. O., Vulikh, K., Zhang, Y., Lee, U., Lei, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0200 · Cited by 15

NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers

Zhu, X., Li, Y., Liu, H., Wang, Y., Sun, R., Jiang, Z., Hou, C., Hou, X., Huang, S., Zhang, H., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.05.007 · Cited by 13

Structure-Based Identification and Biological Characterization of New NAPRT Inhibitors

Franco, J., Piacente, F., Walter, M., Fratta, S., Ghanem, M. S., Benzi, A., Caffa, I., Kurkin, A. V., Altieri, A., Herr, P., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15070855 · Cited by 14

Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease

Hwang, V. J., Zhou, X., Chen, X., Trott, J. F., Aboud, O. A., Shim, K., Dionne, L. K., Chmiel, K. J., Senapedis, W. T., Baloglu, E., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.03.031 · Cited by 12

Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model

Clausing, M., William, D., Preussler, M., Biedermann, J., Grützmann, K., Richter, S., Buchholz, F., Temme, A., Schröck, E., & Klink, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105787 · Cited by 12

Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer

Bai, J., Majjigapu, S. R., Sordat, B., Poty, S., Vogel, P., Elías‐Rodríguez, P., Moreno‐Vargas, A. J., Carmona, A. T., Caffa, I., Ghanem, M. S., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114504 · Cited by 11

Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers

Myong, S., Nguyen, A. Q., & Challa, S. (2024) · Cancers · doi:10.3390/cancers16173085 · Cited by 10

Structure-based virtual screening, molecular dynamics simulation and in vitro evaluation to identify inhibitors against NAMPT

Panwar, S., Kumari, A., Kumar, H., Tiwari, A. K., Tripathi, P., & Asthana, S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1943526 · Cited by 10

Personalized quantitative models of NAD metabolism in hepatocellular carcinoma identify a subgroup with poor prognosis

Chedere, A., Mishra, M., Kulkarni, O., Sriraman, S., & Chandra, N. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.954512 · Cited by 9

Discovery of therapeutic targets in cancer using chromatin accessibility and transcriptomic data

Forbes, A. N., Xu, D., Cohen, S. M., Pancholi, P., & Khurana, E. (2024) · Cell Systems · doi:10.1016/j.cels.2024.08.004 · Cited by 16

Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening

Özgencil, F., Eren, G., Özkan, Y., Ergün, S. G., & Çetin-Atalay, R. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115217 · Cited by 9

Insight Into Nicotinamide Adenine Dinucleotide Homeostasis as a Targetable Metabolic Pathway in Colorectal Cancer

Colombo, G., Gelardi, E. L. M., Balestrero, F. C., Moro, M., Travelli, C., & Genazzani, A. A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.758320 · Cited by 9

Discovery of potent NAMPT-Targeting PROTACs using FK866 as the warhead

Zhang, P., Wang, W., Guo, M., Zhou, L., Dong, G., Xu, D., & Sheng, C. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129393 · Cited by 9

Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells

Ogino, Y., Sato, A., Kawano, Y., Aoyama, T., Uchiumi, F., & Tanuma, S.-I. (2019) · Anticancer Research · doi:10.21873/anticanres.13859 · Cited by 9

Mechanisms of resistance to NAMPT inhibitors in cancer

Redler, J., Nelson, A. E., & Heske, C. M. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.216 · Cited by 8

Understanding Cancer Metabolism Through Global Metabolomics

Milburn, M. V., Lawton, K. A., McDunn, J. E., Ryals, J. A., & Guo, L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1689-0_12 · Cited by 8

Fragment-based discovery of a potent NAMPT inhibitor

Korepanova, A. V., Longenecker, K. L., Pratt, S. D., Panchal, S. C., Clark, R. F., Lake, M. R., Gopalakrishnan, S. M., Raich, D., Sun, C. C., & Petros, A. M. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.12.023 · Cited by 8

Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors

Murray, M. A., Noronha, K. J., Wang, Y., Friedman, A. P., Paradkar, S., Suh, H., Sundaram, R. K., Brenner, C., Saltzman, W. M., & Bindra, R. S. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0012 · Cited by 7

Nampt: a new therapeutic target for modulating NAD+ levels in metabolic, cardiovascular, and neurodegenerative diseases

Manickam, R., Santhana, S., Xuan, W., Bisht, K. S., & Tipparaju, S. M. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2024-0400 · Cited by 9

The Warburg Effect and Beyond: Metabolic Dependencies for Cancer Cells

Hockenbery, D. M., Tom, M. F., Abikoff, C., & Margineantu, D. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_2 · Cited by 6

Discovery of novel therapeutic targets in cancer using patient-specific gene regulatory networksPreprint

Forbes, A. N., Xu, D., Cohen, S. M., Pancholi, P., & Khurana, E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.31.478503 · Cited by 6

Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells

Ribeiro, J., Hansen, K., van Beek, L., Stubbs, C. J., Frigola, J., Talbot, S., Bentouati, S., Hall, J. A. M., Wijnhoven, P. W. G., Armenia, J., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1398 · Cited by 6

Glioblastoma Sensitization to Therapeutic Effects by Glutamine Deprivation Depends on Cellular Phenotype and Metabolism

Isakova, A. A., Николаевна, Д. И., Mozherov, A. M., Mazur, D. V., Антипова, Н. В., Krasnov, K. S., Фадеев, Р. С., Gasparian, M. E., & Yagolovich, A. V. (2024) · Biochemistry (Moscow) · doi:10.1134/s0006297924100079 · Cited by 5

Combined Targeting of NAD Biosynthesis and the NAD-dependent Transcription Factor C-terminal Binding Protein as a Promising Novel Therapy for Pancreatic Cancer

Dcona, M. M., Chougoni, K. K., Dcona, D. T., West, J. L., Singh, S. J., Ellis, K. C., & Grossman, S. R. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0521 · Cited by 5

Nicotinamide phosphoribosyltransferase is a molecular target of potent anticancer agents identified from phenotype-based drug screening

Yamaguchi, D., Imaizumi, T., Yagi, K., Matsumoto, Y., Nakashima, T., Hirose, A., Kashima, N., Nosaka, Y., Hamada, T., Okawa, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43994-x · Cited by 5

Small Molecule Regulators Targeting NAD+ Biosynthetic Enzymes

Cen, Y., Curry, A. M., & White, D. S. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210531144629 · Cited by 6

Probing the Druggability Limits for Enzymes of the NAD Biosynthetic Network in Glioma

Padiadpu, J., Mishra, M., Sharma, E., Mala, U., Somasundaram, K., & Chandra, N. R. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00733 · Cited by 5

NAD+ as a Target for Cancer Treatment

Helman, T. J., & Braidy, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_269-1 · Cited by 4

Efficacy of NAMPT Inhibitors in Pancreatic Cancer After Stratification by MAP17 (PDZK1IP1) Levels

Verdugo‐Sivianes, E. M., Martínez‐Pérez, J., Navas, L. E., Sáez, C., & Carnero, A. (2025) · Cancers · doi:10.3390/cancers17152575 · Cited by 3

Metabolomic Profiling of Ovarian Carcinomas Using Mass Spectrometry

Fong, M., McDunn, J. E., & Kakar, S. S. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-547-7_18 · Cited by 3

Predictive Toxicology: Latest Scientific Developments and Their Application in Safety Assessment

Armstrong, D., Li, S., Frieauff, W., Martus, H. ‐., Reilly, J., Mikhailov, D., Whitebread, S., & Urbán, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12367-4 · Cited by 3

Molecular and cellular consequences of tumour-autonomous IL-6 signalling in intrahepatic cholangiocarcinoma

Gehl, V., O’Rourke, C. J., Cornillet, M., Nousias, O., Fardellas, A., Yangngam, S., Rogalska, M., Aldana, B. I., Høgdall, D., Marquardt, J. U., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-337579 · Cited by 2

Metabolic reprogramming of myeloid cells in cancer: from lactate–NAMPT axis to AI-guided therapeutics

Lee, I.-G., & Jung, K. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01759-3 · Cited by 2

Discovery of a Potent NAMPT-Targeting PROTAC for the Suppression of Triple-Negative Breast Cancer via Macrophage Reprogramming

Song, Y., Yang, C., Li, Q., Huang, S., Chen, S., Xia, Z., Yao, X., Sheng, C., & Dong, G. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00454 · Cited by 2

Targeting DNA Repair Pathways for Cancer Therapy

Vens, C., & Sobol, R. W. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_6 · Cited by 2

Effect of Phosphoribosyltransferase Down-regulation on Malignant Glioma Cell Characteristics

Kamada, M., Ikeda, K., & Manome, Y. (2020) · Anticancer Research · doi:10.21873/anticanres.14492 · Cited by 2

The Small Molecule GMX1778 Is a Potent Inhibitor of NAD Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid

Tumors, P. D., Shore, G. C., & Beauparlant, P. (2009)

NAPRT1 and p53 Status in Cancer and Normal Cells Modulate Induction of ROS Induced by GMX1777/1778: Implication for Synthetic Lethality in Tumors Defective in NAPRT1 and p53

Yoo, S., Cerna, D., Li, H., Flaherty, S. M., Takebe, N., & Coleman, C. N. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.07.1527 · Cited by 1

GMX1777: a novel inhibitor of NAD+ biosynthesis via inhibition of nicotinamide phosphoribosyl transferase.

Roulston, A., Watson, M. H., Bernier, C., Chan, H. H. L., Gratton, M., Jang, A., Koch, E. M., Lavoie, M., Paquette, D., Mitchell, M. W., et al. (2007) · Molecular Cancer Therapeutics · Cited by 3

Abstract B98: Induction of metabolic and oxidative stresses by the novel inhibitor of NAD+ biosynthesis, GMX 1778, for specific killing of human glioblastomas

Yoo, S. S., Cerna, D., Carter, D. J., Flaherty, S. M., Li, H., Takebe, N., & Watson, M. H. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-b98

Abstract 2127: Identification of a novel NAMPT inhibition resistance mechanism utilizing the de novo NAD+ biosynthesis pathway

Guo, J. Q., Tse, C., & Pappano, W. N. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-2127